Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial.
Echegaray MVF, Mello RP, Magnavita GM, Leal GC, Correia-Melo FS, Jesus-Nunes AP, Vieira F, Bandeira ID, Caliman-Fontes AT, Telles M, Guerreiro-Costa LNF, Marback RF, Souza-Marques B, Lins-Silva DH, Santos-Lima C, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC. Echegaray MVF, et al. Trends Psychiatry Psychother. 2023 Sep 17. doi: 10.47626/2237-6089-2022-0593. Online ahead of print. Trends Psychiatry Psychother. 2023. PMID: 37717263 Free article.
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.
Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimarães D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo FS, Vieira F, Sanacora G, Lacerda ALT, Quarantini LC. Leal GC, et al. J Affect Disord. 2023 Jun 1;330:7-15. doi: 10.1016/j.jad.2023.02.151. Epub 2023 Mar 4. J Affect Disord. 2023. PMID: 36871913 Clinical Trial.
Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.
Bandeira ID, Leal GC, Correia-Melo FS, Souza-Marques B, Silva SS, Lins-Silva DH, Mello RP, Vieira F, Dorea-Bandeira I, Faria-Guimarães D, Carneiro B, Caliman-Fontes AT, Kapczinski F, Miranda-Scippa Â, Lacerda ALT, Quarantini LC. Bandeira ID, et al. J Psychiatr Res. 2023 Aug;164:229-234. doi: 10.1016/j.jpsychires.2023.06.028. Epub 2023 Jun 23. J Psychiatr Res. 2023. PMID: 37385001 Clinical Trial.